Testosterone is under clinical development by M et P Pharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Testosterone’s likelihood of approval (LoA) and phase transition for Male Hypogonadism took place on 14 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Testosterone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Testosterone overview

Testosterone (Nasobol, Natesto and vogelxo) is a steroid hormone from the androgen group. It is formulated as gel for nasal administration. It is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired), Hypogonadotropic hypogonadism (congenital or acquired):  idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary- hypothalamic injury from tumors, trauma, or radiation. Natesto also indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

It is under development for the treatment of male hypogonadism.

M et P Pharma overview

M et P Pharma (M et P) is a pharmaceutical and healthcare company. The company provides platform for drug delivery through the intranasal route. It developed various pharma products such as Testosterone, developed for patients with multiple sclerosis; Dopamine, used for the attention deficit hyperactivity disorder; Pregnenolone, developed for mild cognitive impairment; and Progesterone for insomnia and concussion indications. M et P has a mono-dose container which allows the required amount of oil based gel into the nostril. The company also provides pre-clinical and clinical studies on male testosterone deficiency, brain treating malfunctions, PMS and depression, memory enhancing effects and testosterone formulation. M et P is headquartered in Emmetten, Nidwalden, Switzerland.

Quick View Testosterone LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Testosterone
Administration Pathway
  • Nasal
Therapeutic Areas
  • Male Health
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.